Drug-labels.com

Anusol-Hc Ointment Product Monograph

Updated:
Facts
Status:
Prescription (Rx)
Strength:
0.5 % / 0.5 %
Active ingredients:

Product Monograph - Anusol-Hc Ointment

CONTRAINDICATIONS

ANUSOL-HC TM OINTMENT (Hydrocortisone Acetate and Zinc Sulfate Monohydrate) is contraindicated in patients with a sensitivity to any of the components. Not to be used in the presence of existing tuberculous, fungal and viral lesions of the skin.

PRECAUTIONS

Until an adequate proctologic examination is completed and diagnosis made, ANUSOL-HC TM OINTMENT (Hydrocortisone Acetate and Zinc Sulfate Monohydrate) or any preparation containing hydrocortisone should not be used. In addition, specific measures against infection, allergy and other causal factors must not be neglected. Prolonged use of this medication could produce systemic corticosteroid effect although none have noted to date. As with all medication that is applied locally, if idiosyncratic reactions occur, medication should be discontinued.

Pregnancy and Lactation:

The safe use of topical corticosteroids during pregnancy and lactation has not been fully established. Therefore, during pregnancy, ANUSOL-HC TM OINTMENT (Hydrocortisone Acetate and Zinc Sulfate Monohydrate) should not be used unnecessarily in large amounts, or for prolonged periods of time.

ADVERSE REACTIONS

Occasionally, patients may experience burning upon application of the ANUSOL-HC TM OINTMENT (Hydrocortisone Acetate and Zinc Sulfate Monohydrate) especially if the anoderm is not intact. Local sensitivity reactions have been rare.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

The chances of overdosage are very rare, and no toxic reactions or side effects have been reported with ANUSOL-HC TM OINTMENT (Hydrocortisone Acetate and Zinc Sulfate Monohydrate).

Treatment: In case of accidental ingestion, perform gastric lavage, followed by a purgative dose of magnesium sulfate.

DOSAGE AND ADMINISTRATION

Apply ANUSOL-HC TM OINTMENT (Hydrocortisone Acetate and Zinc Sulfate Monohydrate) internally and on the exterior surface of the anus in the morning and at bedtime, and after each bowel movement, or as directed by a physician.

Ointment Composition

Each tube of ANUSOL-HC TM OINTMENT contains: 0.5% hydrocortisone acetate and 0.5% zinc sulfate monohydrate in a petrolatum ointment base. Non-medicinal ingredients: calcium phosphate dibasic, mineral oil, petrolatum white, Polyoxyethylene (2) oleyl-ether.

Stability and Storage Recommendations

Store ANUSOL-HC TM OINTMENT ( Hydrocortisone Acetate and Zinc Sulfate Monohydrate) in a cool place between 15 and 30°C.

AVAILABILITY OF DOSAGE FORMS

ANUSOL-HC TM OINTMENT (Hydrocortisone Acetate and Zinc Sulfate Monohydrate) is available in 30 g aluminum tube co-packaged with a plastic applicator.

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: Hydrocortisone Acetate and Zinc Sulfate Monohydrate

Chemical Name: Hydrocortisone Acetate - Pregn-4-ene-3,20-dione, 21-(acetyloxy)-11,17- dihydroxy-, (11ß)-.

Zinc Sulfate – Zinc sulfate (1:1) monohydrate

Empirical Formula: Hydrocortisone Acetate - C23H32O6

Zinc Sulfate monohydrate - ZnSO4•H2O

Molecular weight: Hydrocortisone Acetate - 404.50

Zinc Sulfate monohydrate - 179.4

Structural Formula for Hydrocortisone Acetate:

Description: Hydrocortisone Acetate: White to practically white, odorless, crystalline powder. Slightly soluble in alcohol and in chloroform; insoluble in water.

Zinc Sulfate monohydrate: Colorless, transparent prisms, or small needles. The monohydrate is practically insoluble in alcohol.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 00505773

Revision date stated in the text: September 28, 2022

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Anusol-Hc Ointment

Rx or OTC
Prescription (Rx)?
DIN 00505773
Schedule(s) PRESCRIPTION
Active ingredient(s) Hydrocortisone acetate 0.5 %, Zinc sulfate 0.5 %
Dosage form(s) Ointment
Route(s) of administration Rectal
Drug class (WHO ATC)
  1. C Cardiovascular system drugs
    1. C05 Vasoprotectives
      1. C05A Agents for treatment of hemorrhoids and anal fissures for topical use
        1. C05AA Corticosteroids, topical for treatment of hemorrhoids and anal fissures
          1. C05AA01 Hydrocortisone
Company CHURCH & DWIGHT CANADA CORP
Current status Marketed
Current status date March 3, 2017

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.